|
|
 |
|
Viewing report
|
|
|
|
Brazil Pharmaceuticals and Healthcare Report Q2 2010
Business Monitor International, April 2010, Pages: 102
The Brazil Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Brazil's pharmaceuticals and healthcare industry.
The outlook for multinational companies in Brazil has improved over the previous quarter, in line with strong confirmed market growth and improved economic stability. In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Q210 Brazil ranks fourth in the Americas region and moves up to joint 15th globally, among the leading emerging pharmaceutical markets. Pharmaceutical sales growth returned to double-digits during 2009, with the rate increasing for the third consecutive year. While BMI had previously projected double-digit increases, the resilience demonstrated by the sector in light of the worst economic performance realised since 1998 has boosted our optimism for the sector even further. We are now projecting a pharmaceutical sales compound annual growth rate (CAGR) of 14.5% through to 2014.
Price rises provided a major boost to patented pharmaceuticals during 2010. The 5.9% maximum price rise authorised in early 2009 was largely realised based on consumer price index (CPI) data for the year. The patented drug market still holds major potential for Big Pharma, with increasing consumer spending set to boost purchasing power for innovative products. A major threat to US firms over the coming months will be Brazil’s reaction to trade disputes. In retaliation against massive subsidies paid to US cotton farmers, which Brazil – among other countries, says is undermining its attempts to trade in a competitive market, the World Trade Organization (WTO) allowed Brazil to make sanctions worth up to US$830mn against the US, including up to US$560mn on goods and US$270mn on intellectual property rights and services.
While the patented drug sector holds healthy optimism for the time being, the generic drugs sub-sector is the fastest growing in Brazil. The market grew by 24% in real terms during 2009, marking yet another year of rapid market share gains for the industry. The result was within 1.4% of BMI projections, which stood at 22.6%. In our view a similar market dynamic will prevail going forward. A study by the Foundation for Consumer Defence and Protection (Fundação Procon) show price variations as high as 1,415% between reference drugs and their generic equivalents, as well as wide differences within their respective groups. Such disparity should continue to drive greater use and competition in the sector. The Brazilian government’s commitment to supporting its domestic pharmaceutical industry was one of the major factors to be put in the spotlight over the previous quarter. Cristália’s opened a BRL30mn (US$16mn) centre for research with the President’s backing, while EMS established ties with biotech companies in China and Cuba with help from the state. The state development bank (BNDES) was involved in the deal which saw Hypermarcas trump Pfizer’s bid for domestic firm Neo Quimica.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Brazil Pharmaceuticals and Healthcare Report Q2 2011
Brazil Pharmaceuticals and Healthcare Report Q1 2012
Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil
Brazil Pharmaceuticals and Healthcare Report Q4 2009
Brazil Pharmaceuticals and Healthcare Report Q1 2010
Brazil Pharmaceuticals and Healthcare Report Q2 2009
Brazil Pharmaceuticals and Healthcare Report Q3 2008
Brazil Pharmaceuticals and Healthcare Report Q2 2008
Colombia Pharmaceuticals and Healthcare Report Q4 2010
Lebanon Pharmaceuticals and Healthcare Report Q4 2010
|
|
|
|
